Sarepta Therapeutics, Inc. — Director's Dealing 2012

Apr 25, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AVI BIOPHARMA INC (AVII)
CIK: 0000873303
Period of Report: 2012-04-24

Reporting Person: Christopher Nishan Garabedian (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2012-04-24	Common Stock	A	81666	—	Acquired	511666	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-04-24	Stock Option (right to buy)	$0.9	A	245000	Acquired	2022-04-24	Common Stock (245000)	Direct

Footnotes

F1: Of the 511,666 shares beneficially owned following the reported transaction, 81,666 relate to restricted stock units granted on the Transaction Date and 430,000 reflect shares of common stock directly beneficially owned by reporting person.

F2: This option is exercisable at the rate of 25% of the shares on April 24, 2013 and 1/48th of the total granted shares on each monthly anniversary thereafter, such that the option will be fully exercisable on April 24, 2016.